Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Lutz

Ophthalmology Kingston, PA Medical Doctor

NPI 1386846251 CMS profile 335642

703 Rutter Ave, Kingston, PA 18704

Open in the dashboard

General payments

$3,967

126 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$44,479 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Daniel Lutz of Kingston, PA is reported in the CMS Open Payments database as having received $3,967 across 126 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $44,479 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 75th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $909 31
2024 General $841 24
2023 General $658 27
2022 General $546 19
2021 General $299 7
2020 General $312 4
2019 General $402 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Lutz
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Daniel Lutz were reported at $909. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Daniel Lutz Ophthalmology median Middle half National median
2019 $402 $258 $104–$655 $163
2020 $312 $126 $45–$321 $114
2021 $299 $205 $76–$534 $132
2022 $546 $266 $100–$678 $149
2023 $658 $308 $117–$745 $160
2024 $841 $340 $127–$846 $164
2025 $909 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $2,259 60 payments
  2. AbbVie, Inc. $659 27 payments
  3. Allergan Inc. $231 6 payments
  4. Glaukos Corporation $226 4 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $115 2 payments
  6. Tarsus Pharmaceuticals, Inc. $114 5 payments
  7. Oyster Point Pharma, Inc. $67 3 payments
  8. Novartis Pharmaceuticals Corporation $61 4 payments
  9. Ocular Therapeutix, Inc. $38 2 payments
  10. New World Medical,Inc. $34 3 payments
  11. Other $162 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,967 126 payments
Products named General payments · program years 2019–2025
  1. Clareon Ophthalmology $586 6 payments
  2. Rocklatan Ophthalmology $478 18 payments
  3. DURYSTA $427 16 payments
  4. HYDRUS Microstent $394 13 payments
  5. Rhopressa $251 3 payments
  6. Simbrinza $183 6 payments
  7. LUMIGAN $173 8 payments
  8. rocklatan Glaucoma $167 5 payments
  9. Clareon Ophthalmology $141 1 payment
  10. PANOPTIX $138 2 payments
  11. Other $1,501 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

4,640

Median for Ophthalmology: 891

Drug cost

$441,012

Median for Ophthalmology: $68,233

Branded share of claims

35.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 249 $107,717
Rhopressa Netarsudil Mesylate Brand 173 $68,999
Brimonidine Tartrate Generic 401 $37,130
Travoprost Generic 187 $32,816
Rocklatan Netarsudil Mesylat/Latanoprost Brand 58 $22,897
Simbrinza Brinzolamide/Brimonidine Tart Brand 81 $21,144
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 79 $19,672
Brinzolamide Generic 57 $17,897
Alphagan P Brimonidine Tartrate Brand 60 $16,628
Prednisolone Acetate Generic 293 $15,451

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$218,001

Medicare's payments for the services billed

Medicare patients

769

Average age 77

Services billed

3,418

461 women, 308 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 29%
Ischemic heart disease 26%
Chronic kidney disease 25%
Atrial fibrillation 18%
Cancer 17%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $188
$188 — —
Rocklatan
  • Alcon Vision LLC $101
$101 58 —
LUMIGAN
  • AbbVie, Inc. $50
$50 249 —
Simbrinza
  • Alcon Vision LLC $41
$41 81 —
Rhopressa
  • Alcon Vision LLC $41
$41 173 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record